東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Group-sequential clinical trials wit...

Hamasaki, Toshimitsu.

FindBook

Google Book

Amazon

博客來

Group-sequential clinical trials with multiple co-objectives

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Group-sequential clinical trials with multiple co-objectives/ by Toshimitsu Hamasaki ... [et al.].
其他作者:	Hamasaki, Toshimitsu.
出版者:	Tokyo :Springer Japan : : 2016.,
面頁冊數:	ix, 113 p. :ill., digital ;24 cm.
內容註:	1. Introduction -- 2. Early Stopping for Efficacy in Clinical Trials with multiple co-primary endpoints -- 3. Sample size recalculation based on observed effects at interim -- 4. Early stopping for futility in Clinical Trials with multiple co-primary endpoints -- 5. Early stopping for futility or Efficacy in Clinical Trials with multiple co-primary endpoints -- 6. Clinical Trials with multiple primary endpoints -- 7. Group-sequential designs for three-arm noninferiority clinical trials -- 8. Further development: topics not covered in this book.
Contained By:	Springer eBooks
標題:	Clinical trials - Statistical methods. -
電子資源:	http://dx.doi.org/10.1007/978-4-431-55900-9
ISBN:	9784431559009

Group-sequential clinical trials with multiple co-objectives
Group-sequential clinical trials with multiple co-objectives[electronic resource] /by Toshimitsu Hamasaki ... [et al.]. - Tokyo :Springer Japan :2016. - ix, 113 p. :ill., digital ;24 cm. - SpringerBriefs in statistics,2191-544X. - SpringerBriefs in statistics..

1. Introduction -- 2. Early Stopping for Efficacy in Clinical Trials with multiple co-primary endpoints -- 3. Sample size recalculation based on observed effects at interim -- 4. Early stopping for futility in Clinical Trials with multiple co-primary endpoints -- 5. Early stopping for futility or Efficacy in Clinical Trials with multiple co-primary endpoints -- 6. Clinical Trials with multiple primary endpoints -- 7. Group-sequential designs for three-arm noninferiority clinical trials -- 8. Further development: topics not covered in this book.

This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control.

ISBN: 9784431559009

Standard No.: 10.1007/978-4-431-55900-9doiSubjects--Topical Terms:

716537
Clinical trials
--Statistical methods.

LC Class. No.: R853.C55

Dewey Class. No.: 615.50724

Group-sequential clinical trials with multiple co-objectives
LDR:02852nmm a2200325 a 4500 001 2041586
003 DE-He213
005 20161130142515.0
006 m d
007 cr nn 008maaau
008 170118s2016 ja s 0 eng d
020 $a 9784431559009 $q (electronic bk.)
020 $a 9784431558989 $q (paper)
024 7 $a 10.1007/978-4-431-55900-9 $2 doi
035 $a 978-4-431-55900-9
040 $a GP $c GP
041 0 $a eng
050 4 $a R853.C55
072 7 $a PBT $2 bicssc
072 7 $a MAT029000 $2 bisacsh
082 0 4 $a 615.50724 $2 23
090 $a R853.C55 $b G882 2016
245 0 0 $a Group-sequential clinical trials with multiple co-objectives $h [electronic resource] / $c by Toshimitsu Hamasaki ... [et al.].
260 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2016.
300 $a ix, 113 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in statistics, $x 2191-544X
505 0 $a 1. Introduction -- 2. Early Stopping for Efficacy in Clinical Trials with multiple co-primary endpoints -- 3. Sample size recalculation based on observed effects at interim -- 4. Early stopping for futility in Clinical Trials with multiple co-primary endpoints -- 5. Early stopping for futility or Efficacy in Clinical Trials with multiple co-primary endpoints -- 6. Clinical Trials with multiple primary endpoints -- 7. Group-sequential designs for three-arm noninferiority clinical trials -- 8. Further development: topics not covered in this book.
520 $a This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control.
650 0 $a Clinical trials $x Statistical methods. $3 716537
650 1 4 $a Statistics. $3 517247
650 2 4 $a Statistical Theory and Methods. $3 891074
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 891086
650 2 4 $a Statistics for Social Science, Behavorial Science, Education, Public Policy, and Law. $3 894294
700 1 $a Hamasaki, Toshimitsu. $3 2200302
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in statistics. $3 1565658
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55900-9
950 $a Mathematics and Statistics (Springer-11649)